Current and future treatments for tuberculosis

Anthony Lee, Yingda Linda Xie, Clifton E. Barry, Ray Y. Chen

Research output: Contribution to journalArticlepeer-review

22 Scopus citations

Abstract

Guidelines on the treatment of tuberculosis (TB) have essentially remained the same for the past 35 years, but are now starting to change. Ongoing clinical trials will hopefully transform the landscape for treatment of drug sensitive TB, drug resistant TB, and latent TB infection. Multiple trials are evaluating novel agents, repurposed agents, adjunctive host directed therapies, and novel treatment strategies that will increase the probability of success of future clinical trials. Guidelines for HIV-TB co-infection treatment continue to be updated and drug resistance testing has been revolutionized in recent years with the shift from phenotypic to genotypic testing and the concomitant increased speed of results. These coming changes are long overdue and are sorely needed to address the vast disparities in global TB incidence rates. TB is currently the leading cause of death globally from a single infectious agent, but the work of many researchers and the contributions of many patients in clinical trials will reduce the substantial global morbidity and mortality of the disease.

Original languageEnglish (US)
Article numberm216
JournalThe BMJ
Volume368
DOIs
StatePublished - Mar 2 2020

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Current and future treatments for tuberculosis'. Together they form a unique fingerprint.

Cite this